Randomized Trial Comparing PrePex Day 7 Foreskin Removal Procedure (FRP) to a Day 0 PrePex FRP .

NCT ID: NCT03223532

Last Updated: 2019-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-26

Study Completion Date

2017-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Prospective, Randomized, Open Label Trial Comparing PrePex™ Day 7 (FRP) to a PrePex Day 0 FRP of Male Circumcision in Resource Limited Settings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objectives:

To compare the safety and acceptability of PrePex Day 7 Foreskin Removal Procedure (FRP) (herein: PrePex) versus PrePex Day0 FRP

Planned Subjects Population:

One hundred and fifty (150) subjects scheduled for voluntary medical male circumcision. The subjects will be randomly divided into two unbalanced study arms (2:1), Day0 FRP arm which will include hundred (100) subjects and PrePex arm which will include fifty (50) subjects.

Study duration per subject will be up to 7 weeks and will include a total of 9 visits.

Study Site: University of Nairobi, Illinois, and Manatoba (UNIM) Research and Training Centre, Kisumu, Kenya

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Male Circumcision

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A Prospective, Randomized, Open Label Trial.
Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PrePex Day 7 FRP

Standard PrePex procedure, 1 week after device placement foreskin and device are removed.

\*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision

Group Type ACTIVE_COMPARATOR

PrePex Day 7 FRP

Intervention Type DEVICE

Standard PrePex procedure, foreskin and device are removed 1 week after device application.

PrePex Day 0 FRP

On the day of device placement the foreskin is removed, the device is removed 1 week later.

Group Type EXPERIMENTAL

PrePex Day 0 FRP

Intervention Type DEVICE

Removal of the foreskin shortly after device application, the device is removed 1 week later

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PrePex Day 7 FRP

Standard PrePex procedure, foreskin and device are removed 1 week after device application.

Intervention Type DEVICE

PrePex Day 0 FRP

Removal of the foreskin shortly after device application, the device is removed 1 week later

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages - 13 to 49 years
* Uncircumcised
* Adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision
* Willing to be circumcised
* Legal guardian consent to the procedure for ages 13-18 years
* Agrees to be circumcised by any of the study methods, Day0 FRP or Day7 FRP as will be determined randomly
* Able to understand the study procedures and requirements
* Agrees to abstain from sexual intercourse for 8 weeks after circumcision
* Agrees to abstain from masturbation for at least 2 weeks after Removal
* Agrees to return to the health care facility for follow-up visits (or as instructed) after his circumcision for a period of 6 weeks post removal (7 weeks total)
* Subject able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have good compliance for the study

Exclusion Criteria

* Legal guardian withholds consent for ages 13-18 years
* Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the subject from undergoing a circumcision
* Subject with the following diseases/conditions: phimosis, paraphimosis, adhesions, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias
* Known bleeding / coagulation abnormality, uncontrolled diabetes
* Subject that to the opinion of the investigator is not a good candidate
* Subject does not agree to anonymous video and photographs of the procedure and follow up visits.
Minimum Eligible Age

13 Years

Maximum Eligible Age

49 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nyanza Reproductive Health Society

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fredrick Otieno, M.D.

Role: PRINCIPAL_INVESTIGATOR

Nyanza Reproductive Health Society

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nyanza Reproductive Health Society

Kisumu, Nyanza, Kenya

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kenya

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VMMC005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Unicirc Adolescent 12-15 Year Old Boys
NCT02593630 COMPLETED PHASE4